From the Food and Drug Administration.
Schwetz
B A
BA
Food and Drug Administration, USA.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000998:Antiviral Agents / Q000627:therapeutic use*; D034341:Aristolochic Acids; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy*; D019587:Dietary Supplements / Q000009:adverse effects*; D004348:Drug Labeling; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D008692:Methadyl Acetate / Q000009:adverse effects*; D009294:Narcotics / Q000009:adverse effects*; D009293:Opioid-Related Disorders / Q000188:drug therapy; D010616:Phenanthrenes / Q000009:adverse effects*; D008517:Phytotherapy; D011355:Prodrugs / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D000077562:Valganciclovir
D000998:Antiviral Agents; D034341:Aristolochic Acids; D009294:Narcotics; D010616:Phenanthrenes; D011355:Prodrugs; C000228:aristolochic acid I; D000077562:Valganciclovir; D008692:Methadyl Acetate; D015774:Ganciclovir